Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Ambros Therapeutics, headquartered in Irvine, California, is a clinical-stage biotech company developing transformative medicines for high unmet medical needs. Its lead program, neridronate (AMBTX-01), targets Complex Regional Pain Syndrome Type 1 (CRPS-1)—a rare, debilitating condition with no FDA-approved treatments. With FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations, the Phase 3 CRPS-RISE trial (NCT07...
Ambros Therapeutics, headquartered in Irvine, California, is a clinical-stage biotech company developing transformative medicines for high unmet medical needs. Its lead program, neridronate (AMBTX-01), targets Complex Regional Pain Syndrome Type 1 (CRPS-1)—a rare, debilitating condition with no FDA-approved treatments. With FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations, the Phase 3 CRPS-RISE trial (NCT07210515) is set to start Q1 2026 enrollment, backed by a $125M Series A.

List your booth number for exhibitions, ask us